Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Part of paid clinical trials in San Diego, California.
- Sponsor
- VA Office of Research and Development
- Study ID
- NCT05994482
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 75 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- adenoma vs no adenoma — OTHERFor Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
- colonoscopy vs no colonoscopy — OTHERFor Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
- survey and expert panel — OTHERThe investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
Study Details
Colorectal cancer is a leading cause of cancer death. Detection and removal of polyps can reduce risk for developing colorectal cancer. After finding and removing precancerous polyps, repeat colonoscopy is routinely recommended. However, it is unclear whether repeat additional colonoscopy further reduces risk for colorectal cancer. For older adults age 75 and older, the lack of this information is especially important, given that the risks of colonoscopy go up with age. This research will evaluate whether older adults with a prior history of precancerous polyps have higher colorectal cancer risks compared to older adults who had a prior normal colonoscopy, and whether, among those with prior precancerous polyps, repeating a colonoscopy after age 75 is associated with reduced cancer risk. The investigators will synthesize these data and gather perspectives from Veterans and clinical stakeholders to make recommendations on whether older adults with a prior history of polyps should continue or defer colonoscopy after age 75.
Key Dates
- Start date
- Oct 1, 2023
- Status verified
- May 2026
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 130,000 participants (estimated)
Arms
- Arm: Older adultsAim 1: Older adults with and without a prior history of precancerous polyps
- Arm: Older adults with prior polypectomyAim 2: Older adults with a prior history of precancerous polyps, exposed vs unexposed to surveillance colonoscopy
- Arm: StakeholdersAim 3: Veterans, clinical, and policy stakeholders who will provide input and participate in an expert panel to synthesis available evidence on pros/cons of surveillance in older adults.
Primary Outcome Measure
colorectal cancer incidence [ Time Frame: at anytime during follow up, ranging up to 20 years. ]
Central Contacts
- Samir Gupta, MD MS(858) 552-8585
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| VA San Diego Healthcare System, San Diego, CA | San Diego | California | 92161-0002 | Samir Gupta, MD MS (PRINCIPAL_INVESTIGATOR) |
| VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles | California | 90073-1003 |
Find similar trials in San Diego, CA
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesPHASE1 · Recruiting · BioEclipse Therapeutics · Scottsdale, Arizona